Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Evogene Announces Joint Microbial Diversity Activity with University of Missouri

Posted on: 13 Sep 16

REHOVOT, Israel, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries, today announced it has entered into an agreement with the University of Missouri to collect and sequence soil samples from several university field sites. The soil samples represent previously untapped sources for microbial diversity from one of the primary corn growing regions of the United States. Under the agreement, Evogene will utilize the results as an additional novel source of leads for its microbial data base supporting its Insect Control and Ag-biological product programs.

Activities associated with the collecting and sampling of the soil will be led by Evogene's R&D site in St. Louis and will be performed in several different field sites situated across the state of Missouri.  The unique set of research stations includes field sites with diverse range of insects, crops, and environments.

"We are excited to collaborate with Evogene, a leading Israeli biotechnology company focusing on crop improvement," said Dr. Marc Linit, Senior Associate Dean for Research and Extension. "Collaboration with Evogene to discover novel soil-borne microbes will lead to the development of new bio-based insect control and other ag-based biological programs that will benefit farmers in Missouri and elsewhere."

"As we continue to expand our activities in the US, we are very pleased to be joining forces with the University of Missouri in a unique project bringing together world class academic researchers in agricultural science with one of the industry's most advanced computational discovery groups," said Ofer Haviv, Evogene President and CEO.  "Tapping into the diversity of University of Missouri's field sites introduces a new source of microbial leads for our already extensive database, allowing us to strengthen the potential novelty of our product offering in the area of insect control and ag-biologicals."

About Evogene Ltd.:
Evogene (NYSE:EVGN) (TASE:EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit or contact the Company at

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", “expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.


Last updated on: 14/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.